HUSSMAN STRATEGIC ADVISORS, INC.
Position in SNDX — Syndax Pharmaceuticals Inc
CIK 1179475
ELLICOTT CITY, MD
Position in SNDX
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$1,836,240
New position
Shares Held
84,000
first reported quarter
Ownership
0.094%
of shares outstanding
% of Portfolio
0.42%
of 13F equity value
Holder Rank
#99
of 242 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026HUSSMAN STRATEGIC ADVISORS, INC. holds $50,152,977 across 23 Biotechnology names. SNDX ranks #13 (3.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
42,000 | $4,761,120 | |
| 2 | AUPH |
Aurinia Pharmaceuticals Inc.
|
210,000 | $3,563,700 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
42,000 | $3,287,340 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
5,250 | $3,273,585 | |
| 5 | INBX |
Inhibrx Biosciences, Inc.
|
31,500 | $2,984,625 | |
| 6 | TGTX |
Tg Therapeutics, Inc.
|
52,500 | $2,884,350 | |
| 7 | SRPT |
Sarepta Therapeutics, Inc.
|
147,000 | $2,641,590 | |
| 8 | PTCT |
Ptc Therapeutics, Inc.
|
31,500 | $2,569,455 |
All Filings in SNDX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,836,240 | 84,000 | Shares | Sole | 2026-08-03 | |
| No filing history on record for this holder in this stock. | ||||||